DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency

Not Applicable

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: PEG-rhG-CSF

First Posted Date: 2022-09-07

Last Posted Date: 2022-09-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 45

Registration Number: NCT05531279

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease

Not Applicable

Recruiting

Conditions: aGVHD

Interventions: Other: glucocorticoids
Other: hUC-MSCs

First Posted Date: 2022-09-07

Last Posted Date: 2022-09-07

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 182

Registration Number: NCT05531266

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.

Not Applicable

Recruiting

Conditions: Hemophilia A

Interventions: Genetic: ZS802

First Posted Date: 2022-08-31

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 6

Registration Number: NCT05523128

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Early Phase 1

Recruiting

Conditions: Refractory Leukemia
Acute Myeloid Leukemia, Childhood
Relapsed Leukemia

Interventions: Drug: JK500 cell injection，cyclophosphamide，Fludarabine

First Posted Date: 2022-08-29

Last Posted Date: 2022-11-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 12

Registration Number: NCT05519384

Locations: 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA

Not Applicable

Recruiting

Conditions: Refractory Aplastic Anemia

Interventions: Drug: avatrombopag

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 39

Registration Number: NCT05518331

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Phase 1

Recruiting

Conditions: Relapsed Leukemia
Lymphoblastic Leukemia, Acute, Childhood
Refractory Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Interventions: Drug: Olverembatinib, APG-2575, Dexamethasone

First Posted Date: 2022-08-10

Last Posted Date: 2023-03-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 22

Registration Number: NCT05495035

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Department of Hematology/Oncology, Shanghai Jiaotong University School of Medicine Affiliated Shanghai Children's Medical Center, Shanghai, China
🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 1 locations

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Phase 2

Recruiting

Conditions: Acute Lymphocytic Leukemia

Interventions: Drug: Inotuzumab ozogamicin

First Posted Date: 2022-07-13

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 31

Registration Number: NCT05456698

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Phase 2

Completed

Conditions: Hematological Malignancies

Interventions: Drug: Anti-CD7 CAR-T

First Posted Date: 2022-07-12

Last Posted Date: 2025-03-13

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 14

Registration Number: NCT05454241

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

A Study of FVIII Gene Therapy for Hemophilia A

Early Phase 1

Recruiting

Conditions: Hemophilia A

Interventions: Genetic: Single dose intravenous injection of BBM 002

First Posted Date: 2022-07-12

Last Posted Date: 2025-02-21

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 8

Registration Number: NCT05454774

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

Not Applicable

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: Avatrombopag

First Posted Date: 2022-06-27

Last Posted Date: 2022-06-27

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 80

Registration Number: NCT05433922

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy